Intrinsic Value

6MA doesn't have a meaningful market cap.

The intrinsic value of Ambea publ AB (6MA) under the Base Case is 15.36 EUR per share. Compared with the current market price of 16.55 EUR, the stock appears Overvalued by 7% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

6MA Intrinsic Value
€15.36
Overvaluation 7%
Intrinsic Value
Price €16.55

6MA is more expensive than usual. This is its most expensive valuation in the past 5 years.

Monitor 6MA
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €12.29
Get notified when the price drops into your buy zone
Current Price €16.55
Intrinsic Value €15.36
Margin of Safety 20% €12.29
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to 6MA

Fundamental Analysis

What Ambea publ AB Does

Health Care

Ambea AB is a Nordic care company that runs homes and services for older people, people with disabilities, and people who need support in daily life. Its business is mainly about providing residential care, assisted living, and other social care services through local facilities and care teams. It also works with municipalities and public authorities that place people in these services and pay for the care.

Headquarters
Sweden SE
Employees
41 000
IPO date
Mar 31, 2017
Read the full company overview
View Company Overview

Ambea publ has no economic moat

No Moat Narrow Wide

Ambea publ AB lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.

Read the full moat analysis
Financials
Efficiency

Earnings Waterfall
Ambea publ AB

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one 6MA stock?

The intrinsic value for Ambea publ AB (6MA) under the Base Case is 15.36 EUR.

Is 6MA stock undervalued or overvalued?

Compared with the current market price of 16.55 EUR, the stock appears Overvalued by 7% .

Back to Top